Xenon Pharmaceuticals Inc.
XENENext catalyst
Azetukalner
Major Depressive Disorder
Get an email about XENE's next catalysts
Track Xenon Pharmaceuticals (XENE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 4 more upcoming events in our data (earnings, PDUFA date, Phase 3 readout).See the timeline
5 upcoming, 0 past
XENE Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.17 | FQ end Sep/2026 | Call: tbd
Azetukalner Phase 3 Est. Readout (X-NOVA-OLE)
Estimated primary completion for Azetukalner trial (NCT06922110) in Major Depressive Disorder. Topline data typically follows completion by weeks to months.
SourceFDA PDUFA Date azetukalner (standard review)
For epilepsy. NDA submitted. AI-extracted from: Xenon gets Phase 3 win with epilepsy drug, setting up FDA approval filing
SourceXEN1101 Phase 3 Est. Readout (X-ACKT)
Primary completion for XEN1101 trial (NCT05667142) in Primary Generalized Tonic-Clonic Seizures
SourceAzetukalner Phase 3 Est. Readout (X-NOVA3)
Primary completion for Azetukalner trial (NCT07076407) in Major Depressive Disorder
SourceMarket Overview
Stock performance and key metrics
XEN1101
Primary Generalized Tonic-Clonic Seizures
Azetukalner
Major Depressive Disorder
XPF-005
Acne Vulgaris
XPF-001
Dental Pain
XPF-002
Postherpetic Neuralgia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
XEN1101 | Phase 3 | Primary Generalized Tonic-Clonic Seizures | - | - |
Azetukalner | Phase 3 | Major Depressive Disorder | - | - |
XPF-005 | Phase 2 | Acne Vulgaris | - | - |
XPF-001 | Phase 2 | Dental Pain | - | - |
XPF-002 | Phase 2 | Postherpetic Neuralgia | - | - |
Major Depressive Disorder
2 drugs in this indication
Acne Vulgaris
1 drug in this indication
Postherpetic Neuralgia
1 drug in this indication
Primary Generalized Tonic-Clonic Seizures
1 drug in this indication
Dental Pain
1 drug in this indication
focal seizures
1 drug in this indication
Focal Onset Seizures
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Xenon Pharmaceuticals Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Xenon Pharmaceuticals Inc.'s (XENE) pipeline across Phase 3, Phase 2. Its lead program is Azetukalner (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Xenon Pharmaceuticals Inc.'s next FDA catalyst?→
Xenon Pharmaceuticals Inc.'s (XENE) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track XENE biotech catalysts?→
Add XENE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Xenon Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.